Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Ethicon* joins world-renowned experts in bariatric surgery to share the latest breakthroughs in science and innovation that are advancing surgery in the fight against obesity and metabolic diseases during ObesityWeek 2016, the combined annual meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS) and The Obesity Society (TOS). Ethicon will highlight the growing body of research and evidence on the benefits of bariatric surgery, a new sleeve gastrectomy training module on the Touch Surgery app, and its comprehensive portfolio of bariatric surgery products aimed to improve patient outcomes.
“Ethicon’s mission is to lead the way in resolving the burden of obesity for both patients and healthcare systems by expanding access to care and demonstrating the critical value of treatment through research and evidence, while also enabling new technologies,” said Dr. Elliott Fegelman, Therapeutic Area Expert, Metabolics, Johnson & Johnson Innovation.
To view the multimedia release go to:
http://www.multivu.com/players/English/7965651-ethicon-bariatric-surgery-access-obesity-week-2016/
Abbott announced today that the U.S. Food and Drug Administration has approved the company’s Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States.
Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide, despite decades of therapeutic advances. While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in approximately three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that restrict vessel motion for the life of the person treated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7826651-abbott-fda-approval-stent/
The website www.MyPerfectDish.eu aims to help people with Parkinson’s, their relatives and caregivers in taking care of their nutritional requirements in order to help them enjoy tasty food that meets their dietary needs.
The website is endorsed by the European Parkinson’s Disease Association (EPDA) and sponsored by Zambon, and has been designed as an easy-to-use scientific information tool so people living with Parkinson’s can be confident that what they are reading is reliable.
“As the only European Parkinson’s umbrella organisation, the EPDA is very proud to endorse this project, which is based on solid scientific and medical grounds,” explains EPDA president Knut-Johan Onarheim. “A balanced and varied diet is important for everyone but it is even more important for people living with Parkinson’s disease because the right food intake can improve their quality of life as well as the effects of therapeutic treatments”.
“Zambon is very proud of having supported this project, which will help people with Parkinson’s and all those involved in the management of the disease. We are strongly committed to drive research and develop solutions to help patients in all their needs“. states Elena Zambon, President of Zambon.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7864251-parkinsons-diet-online-resource/
EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7269351-enteromedics-fda-approval-vbloc-maestro-system-weight-loss-device/
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area, announced today that the EU Committee for Medicinal Pro-ducts for Human Use (CHMP) recommended that the European Commission approve the use of Xadago™ (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilized on ‘Standard of Care’.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7406951-chmp-xadago-parkinsons/
Tackling holiday shopping can be exhausting, especially because of all the preparation involved. According to a recent holiday shopping survey, nearly all (98%) Americans have some kind of “game plan” when shopping for gifts during the holidays. Whether deciding when or who to buy for, Wahl, a leader in men's grooming and personal care, is helping shoppers turn their game plan into a one-stop shop, with gifts for everyone and every budget.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7142651-wahl-takes-hassle-out-of-holiday-shopping/
Eight out of 10 people will be affected by back pain at some point during their lives, making it the No. 1 cause of disability worldwide and resulting in as much as $200 billion in lost wages and productivity. Many sufferers struggle for years to find relief, but treatment options often only provide short-term relief or, in the case of pain medication, carry serious side effects, including drowsiness, liver damage and potential for addiction. Now, thanks to Hocoma, a leader in the development of robotic and sensor-based medical devices for functional movement therapy, consumers have a new way to improve and sustain low back health in the comfort of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7370551-hocoma-innovative-medical-device-therapeutic-gaming-technology-valedo-low-back-health/
This week Hill-Rom (NYSE: HRC) is featuring the Progressa® bed system, the next generation of intensive care unit (ICU) bed systems, at the American Organization of Nurse Executives (AONE) annual meeting in Orlando, Fla. The Progressa bed system is a therapeutic system designed to treat and prevent complications of immobility. It features a state-of-the-art design that supports treatment goals and was engineered to help address patient migration via its StayInPlace™ technology.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/66137-hill-rom-new-progressa-bed-system
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, has announced the availability of an extensive set of advanced predictive sciences applications and services. These integrated capabilities enable drug discovery teams to investigate and evaluate hypotheses about the chemical or biological behavior of molecules of therapeutic interest in silico prior to costly experimentation. Accelrys predictive sciences leverages the open, scientifically aware Accelrys Enterprise Platform to deliver an advanced scientific decision support environment that reduces time and expense, improves quality, enhances collaboration and accelerates innovation in bringing new drugs to market.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62190-accelrys-offers-integrated-predictive-sciences-solutions-faster-innovation
Cancun spring break can prove to be great one for couples and families seeking some quality time together. For some Cancun has also proved to be a therapeutic center as it provides some excellent treatment for people recovering from ailments.
‘Tis the Season for last-minute holiday shopping, and this year the rush is on. According to the National Retail Federation, more than 40 percent of people have shopping left to complete. Fortunately, shoppers can look to Wahl for those must-have, much-appreciated gifts for everyone on the list. The company’s “look good at the last minute” holiday lineup includes new, budget-friendly offerings in men’s grooming, massage therapy and pet. Plus, a new online destination, Wahlholidaygifts.com, makes looking good at the last minute easier than ever.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55488-wahl-holiday-gifts-lineup-for-last-minute-shopping-wahlholidaygifts
